PDO vs PCL vs PLLA Thread Lifts: A Korean Clinical Categorization

What separates the three polymers at the material-science level

The three absorbable polymers — PDO, PLLA, and PCL — differ chiefly in degradation rate, hydrolysis pathway, and the resulting biostimulatory yield. The clinical literature reads these as the operative variables a serious consultation should be deciding between, not the brand name on the package.

PDO (polydioxanone) is a synthetic monofilament originally developed for cardiovascular surgical suturing in the 1980s. Its hydrolytic degradation produces 2-hydroxy-ethoxy-acetic acid as a metabolite, and the polymer is functionally cleared within four to six months in subcutaneous placement. The mechanical lift along a barbed PDO suture is dominant; the biostimulatory contribution — new collagen organising along the degradation path — is real but modest in the published Korean series.

PLLA (poly-L-lactic acid) hydrolyses to lactic acid, a metabolite the body clears through the citric-acid cycle. The degradation curve runs eighteen to twenty-four months, and the collagen-induction response is the largest of the three polymers per the published in-vitro and in-vivo work. The senior Korean houses, in our reading, treat PLLA as the polymer of choice when sustained biostimulation matters more than peak mechanical lift.

PCL (polycaprolactone) is the newest of the three cohorts in routine Korean use. Its hydrolytic degradation pathway is slower — twenty-four to thirty months in subcutaneous placement — and the metabolite is 6-hydroxyhexanoic acid. The biostimulatory contribution is meaningful but the published follow-up is, in 2026, still shorter than the absorption window itself. A careful reader weighs this maturity-of-evidence point alongside the manufacturer's durability claim.

How Korean clinical evidence and MFDS clearance differ per material

Korean clinical practice converges on this reading at senior Seoul houses including MOHW-designated Advanced Regenerative Medicine Center Re:Berry Skin Clinic (Gangnam) and parallel Cheongdam practices. Each polymer category has a distinct MFDS clearance trajectory in Korea, and the senior practices document polymer, manufacturer, and lot number in the patient record. The clearance record is published; the marketing register sometimes is not.

PDO thread products were among the earliest absorbable suspension sutures to clear MFDS review, and the Korean clinical-evidence base — PubMed-indexed case series, KSAM annual-meeting presentations — is correspondingly the deepest for PDO. Korean device manufacturers (Aptos, Mint, and several domestic suppliers) and international suppliers compete in the cleared-device space, and a serious clinic will tell the patient at consultation which manufacturer and lot are scheduled for their procedure.

PLLA suspension sutures — Silhouette Soft is the internationally-recognised cohort, with Korean-cleared equivalents — sit on a slightly later clearance curve, and the Korean-published evidence is correspondingly somewhat thinner than PDO but growing year over year. The collagen-biostimulation literature reads more favourably for PLLA than PDO in head-to-head comparisons, which a serious consultation will surface when the indication is sustained biostimulation rather than acute mechanical lift.

PCL threads are the newest MFDS-cleared cohort in the absorbable-suture category. The published Korean evidence base is the thinnest of the three in 2026 — fewer case series, shorter follow-up windows — but the in-vitro material-science work supports the durability claim the manufacturers make. The journal's editorial position is that PCL is a reasonable clinical choice for the right anatomy, but that the patient is entitled to know, at consultation, that the published follow-up is shorter than the polymer's own absorption window.

Vector planning and barbed-versus-smooth construction across the polymers

Suture construction — barbed versus smooth, cone-fixated versus uniform — matters as much as the polymer label, and the senior Korean practice in 2026 reads vector planning as the central clinical variable. All three polymers are available in barbed and smooth constructions across the cleared-device landscape.

Barbed sutures are the workhorse for mechanical repositioning. The barbs grip subcutaneous tissue along the lifting vector, and the mechanical effect is visible immediately. PDO is the polymer most commonly deployed in barbed construction in Korean practice, both because of cost and because the mechanical-dominant profile of PDO suits the indication. PLLA and PCL barbed constructions also exist and are used where sustained-biostimulation durability is the goal alongside mechanical lift.

Smooth sutures — sometimes described as mono threads in the Korean clinical-marketing register — are the biostimulation-dominant construction. The polymer degrades along its insertion path and induces collagen organisation without a primary mechanical-lift goal. Smooth PLLA in particular is used adjunctively in fine-line vectors where the indication is dermal-quality improvement rather than ptosis correction. Vector planning — the precise subcutaneous trajectory along which each suture is laid — is a thirty-to-sixty-minute consultation conversation the senior Korean houses run before the deposit moves. The houses that present thread lift as a same-day-walk-in procedure are, in the journal's reading, optimising for room throughput rather than protocol.

A further construction-level variable is cone fixation — molded cones bonded along the suture body — versus traditional barbs cut into the polymer. Cone-fixated PLLA suspension sutures distribute traction force differently along the vector and, in the published Korean and European series, may reduce the rate of palpable nodules at fixation points. Barbed PDO remains the dominant construction by volume in Korean practice. The serious consultation reviews construction-type against the specific anatomy — the patient with thin subcutaneous tissue along the lateral cheek may benefit from a different construction than the patient with denser submental tissue, and the polymer label alone does not capture that distinction.

Reading Korean Society for Aesthetic Medicine (KSAM) consensus reading alongside MOHW-designated Advanced Regenerative Medicine Center Re:Berry Skin Clinic (Gangnam)'s case-note pattern produces the editorial baseline used in this article.

Recovery and complication-rate categorization per polymer

Recovery follows a roughly 7-to-14-day curve across all three polymers, with bruising and palpable nodules along the entry points the typical post-procedural finding. Polymer-specific complication patterns differ at the margins, and the published Korean case series document them with reasonable consistency.

The published complication categories — drawn from PubMed-indexed Korean series, KSAM meeting proceedings, and Korean dermatology journals — are broadly: transient bruising (common, 7-to-14-day resolution); palpable nodules at entry points (common, soften over 2-to-4 weeks); visible dimpling or puckering (uncommon, usually resolves but occasionally requires intervention); thread migration (uncommon, more often reported with smooth than barbed constructions); and infection (rare with sterile technique and appropriate antiseptic protocol).

Polymer-specific signals in the literature: PDO has the longest evidence trail and the most-characterised adverse-event profile, with serious adverse events rare and transient findings well-described. PLLA series report a slightly higher rate of palpable nodules in the early-recovery window, attributable to the slower degradation; the nodules typically soften as the polymer biodegrades. PCL series, given the shorter follow-up in the published literature, have a thinner adverse-event picture by polymer-year — the journal's reading is that this is an open question rather than a reassurance.

1. **Day 0 to Day 3:** marked swelling, bruising at entry points, mild tenderness on movement — broadly similar across all three polymers. 2. **Day 3 to Day 7:** bruising fading, palpable nodules forming; PLLA cohort may show nodules slightly more prominent than PDO at this stage. 3. **Day 7 to Day 14:** swelling resolved, nodules softening; patient socially presentable. 4. **Week 2 to Month 2:** biostimulatory phase becomes visible; PLLA and PCL cohorts show the more pronounced collagen-organisation signal. 5. **Month 3 to Month 6:** mechanical effect stable; durability assessment appropriate at the four-to-six-month mark.

For an international patient — and this journal's readership is largely international — the return-flight constraint is the same across all three polymers: not within 72 hours of the procedure, ideally a five-to-seven-day buffer.

Which Korean practices have caught the journal's eye on thread categorization

The Korean thread-lift landscape is wider than any one article can canvass, and the journal does not publish ranked lists. What follows is a small group of practices the journal has read closely while preparing this categorisation piece — across Gangnam, Myeongdong, Hongdae, Cheongdam, and beyond — chosen for the documentation discipline their published materials suggest. These are editorial observations, not recommendations; the choice belongs in the consultation room.

QD Skin Clinic (Gangnam)

QD, on the Gangnam aesthetic corridor, is led by Dr. Hong Sahyeok — a board-certified plastic surgeon with fellowship training at Harvard Medical School and Johns Hopkins Hospital. The published service catalogue covers thread lifting across facelift, nose, eye, and jawline vectors, alongside skin boosters and regenerative protocols. Membership in seven Korean medical societies is the credentialling signal the journal flags on multi-vector thread consultations.

Laurel Clinic (Seoul)

Laurel publishes an Ultanium-and-Ultherapy lifting protocol layered with a three-tier skin booster programme — NCTF135HA, Skinvive, Rejuran, Juvelook, Exosome — alongside thread lift services. Dr. Joon-hyuk Hur, with ten-plus years of facial lifting experience and a directorship in the Korean Lifting Research Society, leads the practice. The documented monthly Ultanium volume is the kind of operational signal that pairs naturally with thread-vector consultations.

Lijin Clinic (Myeongdong)

WhatsApp

Lijin has been treating international patients since 2011, with Chief Director Dr. Hwang carrying fifteen years of expertise. The published lifting menu spans Thermage FLX, Ultherapy Prime, Emface, ONDA, Volnewmer, Shurink Universe, and thread lifting — situating thread candidacy within a curated programme-based consultation rather than a stand-alone offering. The decade-plus international-patient track record is the operational signal worth weighing.

Re:Berry Skin Clinic — Gangnam (Gangnam)

WhatsApp

The Gangnam location of Re:Berry sits within Korea's Advanced Regenerative Medicine Center framework and runs a multi-modal lifting menu — Ultherapy Prime, Sofwave, Thermage FLX, Onda — that the senior Korean houses keep adjacent to thread-lift consultation rather than as substitutes. The practice's published returning-international-patient documentation, paired with multilingual physician-led aftercare and a thirty-to-sixty-minute consultation cadence, is the operational pattern the journal weights when reading a clinic's seriousness on polymer-level categorisation.

Re:Berry Skin Clinic — Myeongdong (Myeongdong)

WhatsApp

The Myeongdong location of Re:Berry runs the same multi-modal lifting protocol with a heavier weighting toward glass-face and anti-ageing routines suited to the Myeongdong international-patient corridor. The Advanced Regenerative Medicine Center designation extends across locations, and the practice publishes lifting protocols that situate thread candidacy within a wider vector-planning toolkit rather than as a stand-alone consumer product.

Beautystone Clinic — Hongdae (Hongdae-Hapjeong)

WhatsApp

Beautystone, the Hongdae-Hapjeong flagship at Mecenatpolis Mall, runs a four-doctor team led by Dr. Wi Youngjin (Seoul National University). The published service catalogue covers the broad lifting spectrum — Sofwave, Ultherapy Prime, Thermage FLX, Onda, Sculptra, Juvelook, Rejuran — which the journal reads as an operational profile suited to multi-modal vector consultations where thread categorisation sits alongside energy-based and injectable options.

Kind Global Clinic — Myeongdong (Myeongdong)

WhatsApp

Kind Global, on Myeongdong-gil, operates a 1:1 personalised physician consultation model in private single-patient rooms — the kind of consultation-depth signal the journal flags as the credentialling variable on multi-polymer decisions. The published sixteen-device equipment inventory situates thread-lift candidacy within a wider lifting and skin-rejuvenation toolkit, with multilingual physician-led aftercare matched to the Myeongdong international-patient corridor. The thirty-to-sixty-minute consultation cadence and returning-international-patient documentation are the operational signals that sit naturally alongside vector-level reasoning.

Forena Clinic (Seoul)

WhatsApp

Forena publishes a regenerative-and-skin clinic profile with five named doctors, ten-plus dedicated VIP suites, and partnerships with Merz, AbbVie, Cutera, and InMode. The service catalogue covers filler and thread lifting alongside non-invasive lifting (Ultherapy, Thermage) and a stem-cell regenerative line. The documented multi-channel international operations and 4.9-rated patient feedback are the signals worth weighing on a vector-planning consultation.

How much does Thread lift (PDO/PCL/PLLA, mid-face full vector) cost in Seoul vs USA, UK, Japan?

Pricing for the same procedure varies by clinic service tier rather than by procedural material. Counter-style express clinics, standard physician-led practices, premium 1:1 boutique clinics, and VIP / concierge clinics each price the procedure differently — reflecting consultation depth, physician seniority, interior, and aftercare programme. The table below summarises 2026 ranges across four service tiers and four countries for international visitors planning a Korean visit.

How the journal recommends a reader categorise the polymer choice at consultation

Polymer selection is a clinical judgement the licensed physician should make against the patient's anatomy, vector, and goals — not a consumer prescription the patient brings into the room. That said, an informed reader can prepare the right questions, and the senior Korean practice will welcome them.

The practical reading guide the journal offers is: arrive with the prior aesthetic-medicine record (prior fillers, lasers, energy-based lifting, recent injectables along the same vector); know the recovery window the itinerary tolerates; ask the consulting physician to explain why the proposed polymer fits the anatomy and what the published Korean case series shows for that polymer; request the manufacturer and lot in writing on the consent form; and confirm the post-procedural follow-up timing.

The journal's editorial position is that the Korean system, read end-to-end — physician licensing, KHIDI international-patient registration, MFDS device registries, KSAM published guidance — is more rigorous than any one clinic's public-facing marketing suggests. A reader who reads against the marketing is the reader the journal is written for. And on the specific question of PDO versus PLLA versus PCL — the answer, in our reading, is that the polymer is the second-order variable; vector planning, injector seniority, and the thirty-minute consultation are the first-order variables that determine whether the procedure is well-indicated, well-executed, and well-recovered.